Business
ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance of Warrants Pursuant to Previously Announced Loan Agreements and Promissory Note Amendment
ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance o...
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"\n\n\nZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance of Warrants Pursuant to Previously Announced Loan Agreements and Promissory Note Amendment\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\nNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES\nSASKATOON, SK, Nov. 7, 2025 /CNW/ - ZYUS Life Sciences Corporation (the \"Company\") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that it has closed a first tranche (the \"First Tranche\") of a non-brokered private placement (the \"Offering\") of up to 2,307,692 units (each a \"Unit\") at a price of $0.65 per Unit for gross proceeds of up to $1,500,000. Under the First Tranche of the Offering, 1,923,077 Units were issued for gross proceeds of approximately $1,250,000.50.\n\n\n\n\n\n\n\nEach Unit consists of one common share of the Company (a \"Common Share\") and one Common Share purchase warrant (a \"Warrant\"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the \"Acceleration Provision\"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of five consecutive trading days on the TSX Venture Exchange (the \"TSXV\"), the Company will have the right to accelerate the expiry date of the Warrants.\nProceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering.\nThe Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued by way of the First Tranche are ...